



FOR IMMEDIATE RELEASE

9 January 2008

PLANT HEALTH CARE PLC
("Plant Health Care" or "the Company")

Field Trials Update

– Strong commercial field trial results in Harpin based N-Hibit and ProAct -

Plant Health Care (AIM: PHC.L), a leading provider of natural products for plants and soil, will announce today, at the Beltwide Cotton Conferences in Nashville, Tennessee that results of replicated N-Hibit® and ProAct™ field trials in 2007 demonstrated yield improvements in cotton of between 6% and 12% when used in combination with nematicides.

N-Hibit® and ProAct™ are EPA registered, Harpin based products which have, in field trials, consistently demonstrated their efficacy in improving crop yields by reducing harmful cyst nematodes. Harpin proteins are produced by diseases which are harmful to plants and, as a result, the application of a Harpin based technology, such as N-Hibit® or ProAct™, causes the plant to behave as though being attacked, even in the absence of disease pressure. Consequently, the plant activates its natural self-defence and growth system, improving yield, root mass and overall plant biomass.

Plant Health Care develops, manufactures and markets a range of innovative Harpin Protein-based products (Harp-N-Tek®). Harpin based proteins have demonstrated a reduction in nematode populations by on average 50 percent, in numerous replicated and commercial field testing work undertaken over several years by leading university plant pathologists and nematologists, crop consultants and cotton producers.

Commenting on the trials, John Brady, Chief Executive of Plant Health Care, said:

"In the Company's interim results statement, the board highlighted its belief in the substantial commercial potential for our Harpin technology and undertaking trials is an important part of the development process. The agreement signed with Monsanto in December 2007, was a significant step in developing this exciting technology and the success of these trials further validates the board's belief in its potential."

"In demonstrating such strong yield improvements in these recent tests, particularly in conjunction with other, already established and widely used nematicides, the prospects for Harpin are further strengthened and the board will continue to explore opportunities available to it in order to exploit fully the potential of this exciting technology."

-Ends-

For further information please contact:

Plant Health Care plc
John Brady, Chief Executive
Tel: 001 603 525 3702

Tavistock Communications
Jeremy Carey/Matt Ridsdale
Tel: 020 7920 3150

Evolution Securities Limited
Tim Worledge/ Tim Redfern
Tel: 020 7071 4300